News Releases

Date	Title and Summary	View
Oct 18, 2022	Johnson & Johnson Reports Q3 2022 Results Reported sales growth of 1.9% to $23.8 Billion with operational growth of 8.1%* and adjusted operational growth of 8.2%* Earnings per share (EPS) of $1.68 increasing 22.6% and adjusted EPS of $2.55 decreasing by 1.9%* Company is maintaining 2022 full-year guidance midpoints for adjusted operational
Oct 13, 2022	Biosense Webster Launches HELIOSTAR™ in Europe, the First Radiofrequency Balloon Ablation Catheter, Enabling Physicians to Perform More Efficient Cardiac Ablations
Oct 10, 2022	Results of Novel Clinical Study of Guselkumab and Golimumab Combination Therapy Show Adults with Moderately to Severely Active Ulcerative Colitis Maintained Higher Rates of Clinical, Histologic, and Endoscopic Remission at Week 38
Oct 10, 2022	STELARA® (ustekinumab) Demonstrated Sustained Symptomatic and Corticosteroid-Free Remission Through Four Years in Adults with Moderately to Severely Active Ulcerative Colitis
Oct 03, 2022	Johnson & Johnson to Participate in the Credit Suisse 31st Annual Healthcare Conference
Oct 01, 2022	Janssen Announces Late-Breaking Data from Two Gene Therapy Programs at the American Academy of Ophthalmology 2022 Annual Meeting
Sep 28, 2022	Johnson & Johnson Vision Introduces All Purpose EDOF, TECNIS Symfony OptiBlue IOL, the Latest PC-IOL Powered by InteliLight Technology
Sep 28, 2022	Johnson & Johnson Announces Kenvue as the Name for Planned New Consumer Health Company
Sep 27, 2022	Johnson & Johnson Vision Introduces All Purpose EDOF, TECNIS Symfony OptiBlue IOL, the Latest PC-IOL Powered by InteliLight Technology
Sep 14, 2022	Johnson & Johnson Announces $5 Billion Share Repurchase Program NEW BRUNSWICK, N.J. --(BUSINESS WIRE)--Sep. 14, 2022-- Johnson & Johnson (NYSE: JNJ) today announced that the Board of Directors has authorized the repurchase of up to $5 billion of the company's common stock. “The last few years have demonstrated the resilience of Johnson & Johnson .